Stocks Health care SGP
NASDAQ · Health careSpyGlass Pharma, Inc. (SGP)
It posted a net loss of $39.9M. In fiscal 2025 capital spending exceeded operating cash flow by $33.5M. At June 30, 2026 it held $223.1M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.
What SpyGlass Pharma, Inc. does
SpyGlass Pharma, Inc. is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NASDAQ under the ticker SGP.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$39.9M | -$17.98 | -$33.5M |
| 2025 | n/a | -$29.2M | -$16.31 | -$24M |
Latest SEC filings
What SpyGlass Pharma, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026
- August 6, 2026
- May 14, 2026Quarterly report 10-Q · period to March 31, 2026
- May 14, 2026
- March 26, 2026Annual report 10-K · period to December 31, 2025
- March 26, 2026
- March 9, 2026Other event 8-K
- February 17, 2026Passive stake (5% or more) SCHEDULE 13G
- February 17, 2026Activist stake (5% or more) SCHEDULE 13D
- February 13, 2026Activist stake (5% or more) SCHEDULE 13D
Questions about SGP
What does SpyGlass Pharma, Inc. do?
SpyGlass Pharma, Inc. is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NASDAQ under the ticker SGP.
Is SpyGlass Pharma, Inc. profitable?
No. In fiscal 2025 it reported a net loss of $39.9M.
When did SpyGlass Pharma, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026.
Similar companies
Follow SGP
Get an email when SpyGlass Pharma, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow SGP: get an email when it filesWhere the numbers come from
Financial figures are the values SpyGlass Pharma, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.